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Objectives. This study was sought to investigate whether pe-
ripheral blood levels of matrix metalloproteases (MMPs) are
affected in patients with acute coronary syndromes (ACS).
Background. Synthesis of MMPs has been reported in coronary
atherosclerotic lesions in patients with unstable angina (UA),
suggesting a pathogenic role of MMPs in the development of ACS.
Methods. Using sandwich enzyme immunoassay, serum
MMP-2 and plasma MMP-9 were measured in 33 patients with
ACS (22 with acute myocardial infarction [AMI], 11 with UA), 17
with stable effort angina (EA) and 17 normal control subjects.
Results. Serum MMP-2 in patients with UA and AMI on day 0
was two times greater than that in control subjects, and patients
with EA showed higher MMP-2 levels than those in control
subjects. Plasma MMP-9 in patients with UA and AMI on day 0
was elevated by threefold and twofold versus that in control
subjects, respectively. In patients with UA and AMI who under-
went medical treatment (n 5 11 and 13, respectively), MMP-2
elevation was sustained until day 7. In patients with UA, MMP-9
elevation on day 0 was followed by a gradual decrease toward the
control range up to day 7. Some patients with AMI showed a
transient MMP-9 elevation with a peak on day 3, whereas in
others, MMP-9 levels were significantly elevated on day 0 and
remained higher than those in control subjects up to day 3.
Conclusions. Serial changes in serum MMP-2 and plasma
MMP-9 were documented in patients with ACS. These findings
provide an insight into the molecular mechanism of plaque
destabilization.
(J Am Coll Cardiol 1998;32:368–72)
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Rupture of plaques with superimposed thrombosis is now
considered to be the main cause of the acute coronary syn-
dromes (ACS) that range from unstable angina (UA) to Q
wave acute myocardial infarction (AMI) (1,2). Several patho-
physiologic mechanisms are involved in the process of plaque
rupture, including inflammation, rheologic factors, circumfer-
ential wall stress and vasoconstriction, as well as destabilizing
changes in the plaque tissues (1,2). Matrix metalloproteases
(MMPs) are critical for vascular remodeling by regulating
degradation of the extracellular matrix (ECM) (3). Recently,
there is increasing evidence that 72-kDa and 92-kDa type IV
collagenases (MMP-2 and MMP-9, respectively), which act
specifically on the basement membranes and partially de-
graded collagen, play a pathogenic role in the development of
the atherosclerotic plaques. It has been shown (4,5) that
MMP-2 is constitutively expressed in vascular smooth muscle
cells (VSMCs) in normal arteries and that in addition to
increased MMP-2 expression, atherosclerotic plaques prone to
rupture show induction and activation of MMP-9 in VSMCs
and infiltrating macrophages. Furthermore, MMP-2 and
MMP-9 are considered to play a role in the regulation of
migration and proliferation of VSMCs in atherosclerotic le-
sions by acting specifically on basement membrane compo-
nents that modulate the cell-to-cell communication with acti-
vated surrounding cells, such as inflammatory cells, endothelial
cells and VSMCs (3).
It has been reported (6,7) that concentrations of MMPs are
elevated not only in affected tissue and body fluid but also in
peripheral blood in some patients with cancer, liver cirrhosis or
rheumatoid arthritis. These findings raise the possibility that
patients with vulnerable atherosclerotic plaques would show
elevated peripheral blood levels of MMPs. Therefore, using
sandwich enzyme immunoassay, we measured serum MMP-2
and plasma MMP-9 in patients with ACS, including UA and
AMI.
Methods
Patients. This study enrolled 33 patients with ACS (22 with
AMI [mean 6 SD age 62 6 9 years, 15 men]; 11 with UA
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[mean age 61 6 10 years, 7 men]), 17 with stable effort angina
(EA) (mean age 62 6 11 years, 12 men) and 17 normal
volunteers (control subjects: mean age 54 6 11 years, 10 men)
(Table 1). The normal volunteers had no past history or
evidence of cardiovascular disease, hypertension or diabetes
mellitus. The present study did not include patients or control
subjects with a history of neoplastic, hepatic, infectious or
autoimmune disease; peripheral atherosclerotic disease; or any
surgical procedure in the preceding 6 months. Written in-
formed consent was obtained from each subject.
Patients with AMI was defined as the presence of typical
prolonged chest pain accompanied by serial changes on the
standard 12-lead electrocardiogram (ECG) or significant (2-
fold more than the upper normal range) increase in creatine
kinase (CK). This study included 22 patients with AMI admit-
ted to the coronary care unit within 3 to 9 h after the onset of
chest pain, of whom 9 with indications for direct percutaneous
transluminal coronary angioplasty or intravenous thrombolytic
therapy underwent these interventional treatments. The re-
maining 13 patients (AMI-M group: mean age 64 6 7 years, 9
men) were admitted to the hospital .6 h after the onset of
symptoms and underwent medical treatment with combina-
tions of standard medications, including oral nitrates, beta-
adrenergic blocking agents, calcium antagonists and aspirin,
and intravenous nitrate or heparin, or both. The diagnosis of
patients with UA was defined as anginal pain at rest occurring
during the preceding 24 h with transient significant ischemic
ST segment or T wave changes, or both, without significant
(1.5-fold more than the upper normal range) increases in CK.
Patients in whom ST segment elevation or new abnormal Q
waves developed during the observation period were not
included. In all patients with UA, intensive medical treatment
as previously described was started on day 0 (the admission
day) if patients had not already taken medicines, and the
clinical symptoms and signs of myocardial ischemia were
controlled after admission. The EA group included patients
who complained of angina on effort without evidence of recent
deterioration or rest pain in the previous 6 months.
Blood sampling and enzyme immunoassay. Blood samples
were drawn from the peripheral vein on admission. In the UA
and AMI-M groups, serial blood samples were also collected
on days 1, 3 and 7 after admission. For plasma preparation,
2Na-EDTA (final 0.1%) was added to whole blood. After
centrifugation, serum and plasma samples were frozen and
stored at 280°C until use. Sandwich enzyme immunoassay was
performed for measuring concentrations of serum MMP-2 and
plasma MMP-9 using commercial available kits with monoclo-
nal antibodies against each substance (6,7) according to the









[n 5 22 (13)]
Age (yr) 54 6 11 62 6 11 61 6 10 62 6 9 (64 6 7)
Men/women 10/7 12/5 7/4 15/7 (9/4)
Hypertension 0 7 6 11 (7)
Diabetes mellitus 0 3 3 7 (4)
Smoker 3 7 6 11 (7)
Hypercholesterolemia
(total chol .220 mg/dl)
1 6 3 10 (4)
History of preceding EA — — 6 11 (5)
Previous myocardial infarction — 3 3 5 (3)
Coronary angiography — 17 9* 20 (11)
No. of $75% stenosed vessels 2.1 6 1.0 1.8 6 0.8 2.1 6 0.8 (2.0 6 0.9)
Medication used
Nitrates — 16 11 21 (13)
Beta-blockers — 4 8 6 (3)
Calcium antagonists — 12 10 17 (10)
Aspirin — 15 10 19 (12)
Heparin — — 11 20 (12)
*Coronary angiography was carried out within 4 weeks after stabilization of symptoms. Data presented are mean
value 6 SD or number of patients. Ages were not different among the four groups, and there was no significant difference
in the other characteristics among the groups with stable effort angina (EA), unstable angina (UA), acute myocardial
infarction (AMI) and AMI with conventional medical treatment (AMI-M).
Abbreviations and Acronyms
ACS 5 acute coronary syndromes
AMI 5 acute myocardial infarction
CK 5 creatine kinase
CRP 5 C-reactive protein
EA 5 effort angina
ECG 5 electrocardiogram, electrocardiographic
ECM 5 extracellular matrix
MMP 5 matrix metalloprotease
UA 5 unstable angina
VSMCs 5 vascular smooth muscle cells
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manufacturer’s instructions (Fuji Chemical Industries Ltd.,
Takaoka, Japan).
Statistical analysis. Results are expressed as mean value 6
SD, except in the figures, where SE values are shown. One-way
factorial analysis of variance followed by the Sheffeˆ F test was
used for intergroup comparisons. A p value ,0.05 was consid-
ered statistically significant.
Results
Baseline characteristics. There were no significant differ-
ences in average age, ratio of male to female or prevalence of
major risk factors among the normal control subjects and three
patient groups (Table 1). Medications did not differ among the
groups. Intravenous heparin was given to all patients in both
the UA and AMI groups. The number of angiographically
significant stenosis did not differ among the EA, UA and AMI
groups. The clinical characteristics of the AMI-M group were
not different from those of the other patients with AMI.
Peripheral blood levels of MMP-2 and MMP-9. Figure 1
demonstrates the peripheral blood levels of MMP-2 and
MMP-9 in the normal volunteers and patients with EA, UA
and AMI on admission. In the control group, serum MMP-2
and plasma MMP-9 levels were 443 6 102 and 27 6 8 ng/ml,
respectively. These levels were similar to those reported pre-
viously in normal volunteers (6,7). Serum MMP-2 in the UA
and AMI groups (976 6 158 and 962 6 273 ng/ml, respectively)
was significantly higher than that in the control (p , 0.001 and
p , 0.001, respectively) or EA group (634 6 125 ng/ml, p ,
0.01 and p , 0.001, respectively). MMP-2 levels in the EA
group were also higher than those in the control group (p ,
0.05). The UA group showed significantly higher plasma
MMP-9 levels (87 6 26 ng/ml) than those in not only the
control group (p , 0.001) but also the EA and AMI groups
(34 6 11 and 49 6 28 ng/ml, p , 0.001 and p , 0.001,
respectively). Although the average of MMP-9 levels in the
AMI group was significantly higher than that in the control
group (p , 0.05), it was apparent that the AMI group included
two distinct subgroups: Six patients demonstrated significantly
higher MMP-9 levels than did control subjects and patients
with EA, and seven had MMP-9 levels similar to those in the
control subjects and patients with EA.
Serial changes in MMP-2 and MMP-9 levels in patients
with ACS. Serial changes in MMP-2 and MMP-9 levels were
assessed in the patients with UA and AMI who underwent
conventional medical treatment to avoid the potential effects
of interventional or thrombolytic therapies. During the obser-
vation period, all patients with UA were well controlled and
did not experience the symptoms or signs of exacerbation of
myocardial ischemia. No AMI-M group patients showed clin-
ical findings of reinfarction or postinfarction angina. In the
patients with UA (Fig. 2A), elevation of serum MMP-2 was
sustained from day 0 to day 7 by about twofold versus that in
the control and EA groups. Plasma MMP-9 levels on day 0
were higher in the UA group by about threefold and twofold
than in the control and EA groups, respectively, and a gradual
decrease toward the control range was observed up to day 7
(Fig. 2B). As shown in Figure 3A, AMI-M group patients
demonstrated a twofold sustained elevation of MMP-2 versus
that in the control and EA groups. It was apparent that the two
subgroups showing distinct time courses of plasma MMP-9
changes were included in the AMI-M group (Fig. 3B). In seven
patients, MMP-9 levels were equivocal to those in the control
and EA groups on day 0 and then were transiently increased,
Figure 2. Serial changes in serum MMP-2 (A) and plasma MMP-9 (B)
in patients with UA who underwent conventional medical treatment.
Columns 5 mean values; bars 5 SE. ***p , 0.001 versus control
group. †p , 0.05, ††p , 0.01 and †††p , 0.001 versus EA group.
Figure 1. Serum MMP-2 (A) and plasma MMP-9 (B) levels were
measured in normal volunteers (Control) and patients with stable EA,
UA or AMI. Peripheral blood was drawn from a peripheral vein of
each patient on admission. Squares and bars 5 mean value 6 SE.
*p , 0.05 and ***p , 0.001 versus control group. ††p , 0.01 and
†††p , 0.001 versus EA group. ‡‡p , 0.01 versus AMI group.
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with a peak on day 3. In the six other patients, significant
MMP-9 elevations (twofold increase vs. control group) were
seen on day 0, and the levels remained higher than those in
control subjects up to day 3. There were no significant differ-
ences in MMP-2 and MMP-9 levels on day 0 between the
AMI-M group and the rest of the AMI group.
Serum CK and CK-MB isoform levels had no significant
correlation with either serum MMP-2 or plasma MMP-9 levels
at any time point in patients with UA or AMI, and neither
maximal MMP-2 nor MMP-9 levels were associated with
maximal CK or CK-MB isoform levels (data not shown). Also,
maximal levels of these MMPs had no correlation with blood
C-reactive protein (CRP) on day 0 or maximal CRP levels
(data not shown).
Myocardial ischemia and MMP-2 and MMP-9 levels. In
patients with EA, serum MMP-2 and plasma MMP-9 levels
were measured before, immediately after and 1 h after the
treadmill exercise test. MMP-2 and MMP-9 levels did not
change during the exercise test (Fig. 4), although exercise-
induced angina and typical ischemic ECG changes were doc-
umented.
Discussion
The present study showed that increases in serum MMP-2
levels were sustained up to day 7 in both UA and AMI group
patients and that plasma MMP-9 was transiently elevated in
patients with UA and AMI, although the time course of
MMP-9 was different between the two groups. To our knowl-
edge, present report is the first to show that peripheral blood
levels of MMP-2 and MMP-9 were increased in patients with
ACS.
MMPs play an important role in ECM remodeling during
all phases of atherosclerosis. The ECM constitutes the bulk of
most advanced atherosclerotic plaques. Therefore, ECM me-
tabolism in atherosclerotic lesions is considered to favor the
overall net accumulation rather than degradation of matrix
components. However, focal accumulation of cells that over-
express activated forms of MMPs may promote local destruc-
tion of ECM in atheroma, leading to plaque destabilization
and rupture (3). Constitutive expression of MMP-2 has been
shown (4) in VSMCs in normal arteries, and MMP-2 expres-
sion was increased in VSMCs in atherosclerotic arteries.
Furthermore, MMP production by VSMCs is associated with
the shift of these cells to the modulated phenotype typical of
atheroma (8). The present study demonstrated higher MMP-2
levels in patients with EA than in control subjects and,
furthermore, that patients with ACS had sustained MMP-2
elevations that were greater than those in patients with EA.
Figure 4. Serum MMP-2 (A) and plasma MMP-9 (B) were measured
before, immediately after and 1 h after the treadmill exercise test in
patients with stable EA. A symptom-limited exercise test was per-
formed, and anginal pain accompanied with typical ischemic ECG
changes occurred in all the patients. Dashed lines 5 average levels in
normal volunteers (serum MMP-2: 443 6 102 ng/ml; plasma MMP-9:
27 6 8 ng/ml); other symbols as in Figure 2.
Figure 3. Serial changes in serum MMP-2 (A) and plasma MMP-9 (B
[top panel]) in patients with AMI who underwent conventional
medical treatment (AMI-M). Symbols as in Figure 2. *p , 0.05, **p ,
0.01 and ***p , 0.001 versus control group. B (bottom panel),
Individual data for AMI-M group patients. Six AMI-M group patients
(solid circles) showed a sustained elevation of MMP-9 levels from day
0 until day 3, whereas in the other seven patients (open circles) MMP-9
levels were equivocal to those in the control and EA groups on day 0
and were then transiently increased, with a peak on day 3.
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Taken together, increases in serum MMP-2 may be associated
with progression and destabilization of coronary atherosclero-
sis or phenotypic changes in VSMCs in such lesions. Induction
of MMP-9 expression as well as interstitial collagenase and
stromelysin has been shown (4,5) in both VSMCs and accu-
mulating macrophages in atherosclerotic plaques, particularly
in the shoulder and core of plaques prone to rupture. These
observations raised the possibility that these MMPs are
strongly associated with the molecular mechanism of the onset
and development of ACS. Accordingly, the transient elevation
of MMP-9 levels in patients with UA may be associated with
the increased expression of MMP-9, probably in activated
macrophages or VSMCs in the plaque prone to rupture. It is
noteworthy that MMP-9 levels declined after admission in
patients with UA in whom clinical symptoms and signs were
stabilized by medical treatment. This observation might reflect
the stabilization of the sources of MMP-9. Two distinct pat-
terns of the time course of MMP-9 levels were observed in
patients with AMI: On day 0, six patients had elevated MMP-9
levels, whereas the other seven patients did not. It is plausible
that the significance of the contribution of MMPs to the
pathogenesis of AMI is widely varied in each case because
other factors, such as a variety of mechanical and hemody-
namic forces, rheologic factors and vasoconstriction, could also
precipitate and trigger disruption of vulnerable plaques (1,2).
The delayed increase or sustained elevation in MMP-9 seen on
day 3 may be due to induced MMP-9 in the infarcted myocar-
dium because delayed activation of MMP-9 has been reported
(9) in the rat myocardium at ;day 4 after experimental
infarction.
All MMPs require activation from precursors to attain
enzymatic activity. The antibodies available do not distinguish
the active form of these enzymes from their proenzyme forms;
and areas that contain MMPs in the plaques also contain tissue
inhibitors of metalloproteases, molecules that can prevent the
matrix-degrading action and activation of MMPs. Therefore,
we believe that increased MMP immunoreactivity does not
necessarily correspond to its augmented enzymatic activity. We
cannot deny the possibility that ischemia may cause leakage of
MMPs from the vessel wall or myocardium. However, it is
unlikely to be a main factor because no elevation of MMP-2 or
MMP-9 was observed in the patients with EA immediately and
1 h after exercise-induced ischemia, even though these patients
showed significant ischemic evidence during the exercise test.
It is also not likely that leakage due to myocardial necrosis was
the main source of MMPs because MMP levels were not
correlated with serum CK or CK-MB isoform in the patients
with AMI. Finally, it is possible that peripheral macrophages
and leukocytes might be a source of elevated MMPs because
monocytes in the systemic circulation can be activated in
patients with ACS (10). Although there was no correlation
between CRP, a marker of systemic inflammation, and MMP
levels, this does not necessarily deny the possibility that
elevated MMP levels could indicate cell activation in plaques.
Further investigations are needed to address these issues.
Conclusions. Serial changes in serum MMP-2 and plasma
MMP-9 were documented in patients with ACS and provide an
insight into the molecular mechanism of plaque destabilization
of coronary atherosclerotic lesions.
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